Risultati della ricerca - Werner Scheithauer

Raffina i risultati
  1. 1
    Clinical trials of agents that reverse multidrug resistance. A literature review

    Clinical trials of agents that reverse multidrug resistance. A literature review di Markus Raderer, Werner Scheithauer

    Pubblicazione 1993
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Ondansetron for Pruritus Due to Cholestasis

    Ondansetron for Pruritus Due to Cholestasis di Markus Raderer, Christian A. Müller, Werner Scheithauer

    Pubblicazione 1994
    Testo Testo
    Carta
    Aggiungi alla lista
    Salvato in:
  3. 3
    MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

    MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside di Burghardt Wittig, Manuel Schmidt, Werner Scheithauer, Hans‐Joachim Schmoll

    Pubblicazione 2014
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  4. 4
    HER 2/neu protein expression in colorectal cancer

    HER 2/neu protein expression in colorectal cancer di B. Schuell, Thomas Gruenberger, Werner Scheithauer, Ch. Zielinski, Fritz Wrba

    Pubblicazione 2006
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

    Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. di Werner Scheithauer, Harald Rosén, Gabriela Kornek, Christian Sebesta, D. Depisch

    Pubblicazione 1993
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Answering Patients' Needs: Oral Alternatives to Intravenous Therapy

    Answering Patients' Needs: Oral Alternatives to Intravenous Therapy di Markus Borner, Werner Scheithauer, Chris Twelves, Jean A. Maroun, H. Wilke

    Pubblicazione 2001
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  7. 7
    A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid

    A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid di Markus Kieler, Matthias Unseld, Daniela Bianconi, Werner Scheithauer, Gerald W. Prager

    Pubblicazione 2019
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

    Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases di Birgit Gruenberger, Werner Scheithauer, Robert Punzengruber, Christoph Zielinski, Dietmar Tamandl, Thomas Gruenberger

    Pubblicazione 2008
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

    Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer di B. Gruenberger, Dietmar Tamandl, Johannes Schueller, Werner Scheithauer, Christoph Zielinski, Friedrich Herbst, Thomas Gruenberger

    Pubblicazione 2008
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

    Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial di Gabriela Kornek, B. Schuell, Friedrich Laengle, Thomas Gruenberger, M. Penz, K. Karall, D. Depisch, Fritz Lang, Werner Scheithauer

    Pubblicazione 2004
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer

    Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer di Gerald W. Prager, Kira Braemswig, Alexandra Martel, Matthias Unseld, Georg Heinze, Thomas Brodowicz, Werner Scheithauer, Gabriela Kornek, Christoph Zielinski

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study

    Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study di Boris Dickmann, Jonas Ahlbrecht, Cihan Ay, Daniela Dunkler, J. Thaler, Werner Scheithauer, Peter Quehenberger, C. C. Zielinski, Ingrid Pabinger

    Pubblicazione 2013
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Thrombosis risk and survival in cancer patients with elevated C‐reactive protein

    Thrombosis risk and survival in cancer patients with elevated C‐reactive protein di R. Kanz, Thomas Vukovich, Rainer Vormittag, Daniela Dunkler, Cihan Ay, J. Thaler, Johanna Haselböck, Werner Scheithauer, Christoph Zielinski, Ingrid Pabinger

    Pubblicazione 2010
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

    Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer di M. Penz, Gabriela Kornek, Markus Raderer, H. Ulrich-Pur, Wolfgang Fiebiger, A. Lenauer, D. Depisch, G. Krauss, Bruno Schneeweiß, Werner Scheithauer

    Pubblicazione 2001
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

    Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemothera... di Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera‐Knorrenschild, D. Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

    XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results di J Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Karen Rittweger, Frank Gilberg, Leonard B. Saltz

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

    Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of... di Chris Twelves, Werner Scheithauer, J. McKendrick, Jean‐François Seitz, Guy van Hazel, A. Wong, Eduardo Díaz‐Rubio, Frank Gilberg, J Cassidy

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

    Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma di H. Ulrich-Pur, Markus Raderer, Gabriela Kornek, B. Schüll, Katharina Schmid, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Fritz Lang, Werner Scheithauer

    Pubblicazione 2003
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

    Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial di Werner Scheithauer, B. Schüll, H. Ulrich-Pur, Katharina Schmid, Markus Raderer, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Friedrich Lang, Gabriela Kornek

    Pubblicazione 2002
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors

    Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors di Irene Virgolini, Markus Raderer, Amir Kurtaran, P. Angelberger, S. Banyai, Qiong Yang, Shuren Li, Martin Banyai, Johann Pidlich, Bruno Niederle, Werner Scheithauer, Peter Valent

    Pubblicazione 1994
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: